Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis
Purpose This review article serves to assess the consistency of recommendations from guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis Clinical Practice Guidelines (CPGs). Methods We conducted a systematic literature search to identify CPGs that provide recomm...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-05-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2021.1914306 |
| _version_ | 1797683518099161088 |
|---|---|
| author | Xiuli Xie Yangyang Wang Sha Yao Yun Xia Hao Luo Lui Li Chuanjian Lu |
| author_facet | Xiuli Xie Yangyang Wang Sha Yao Yun Xia Hao Luo Lui Li Chuanjian Lu |
| author_sort | Xiuli Xie |
| collection | DOAJ |
| description | Purpose This review article serves to assess the consistency of recommendations from guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis Clinical Practice Guidelines (CPGs). Methods We conducted a systematic literature search to identify CPGs that provide recommendations on diagnosis and treatment for psoriasis. Four reviewers performed a quality assessment of the included CPGs with the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Results A total of 51 sets of CPGs from 22 medical societies or separate working groups fulfilled the inclusion criteria. The overall quality of the eligible sets of guidelines was moderate to high, with an overall average score of 55%. The highest domain scores were Score and Purpose (70%) and Clarity of Presentation (68%). A total of 95 biologic agent recommendations were extracted from the 18 recommended CPGs. Three biologic agents (Etanercept, Adalimumab, Ustekinumab) were recommended for pediatric patients. Three biologic agents (Adalimumab, Ustekinumab, Secukinumab) were recommended as first-line biologic agents for adults with psoriasis. Conclusion The overall methodological quality of CPGs for psoriasis is medium to high. More attention should be paid to applicability in guideline development. The recommendations and the basis for them among various sets guidelines were almost consistent. |
| first_indexed | 2024-03-12T00:15:36Z |
| format | Article |
| id | doaj.art-037a6339e40a4d8a876bb0b61ab8274a |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:36Z |
| publishDate | 2022-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-037a6339e40a4d8a876bb0b61ab8274a2023-09-15T14:28:50ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-05-013342038205010.1080/09546634.2021.19143061914306Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasisXiuli Xie0Yangyang Wang1Sha Yao2Yun Xia3Hao Luo4Lui Li5Chuanjian Lu6Department of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineSchool of Basic Medical Sciences, Guangzhou University of Chinese MedicineSchool of Basic Medical Sciences, Guangzhou University of Chinese MedicineDepartment of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese MedicineSchool of Basic Medical Sciences, Guangzhou University of Chinese MedicinePurpose This review article serves to assess the consistency of recommendations from guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis Clinical Practice Guidelines (CPGs). Methods We conducted a systematic literature search to identify CPGs that provide recommendations on diagnosis and treatment for psoriasis. Four reviewers performed a quality assessment of the included CPGs with the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Results A total of 51 sets of CPGs from 22 medical societies or separate working groups fulfilled the inclusion criteria. The overall quality of the eligible sets of guidelines was moderate to high, with an overall average score of 55%. The highest domain scores were Score and Purpose (70%) and Clarity of Presentation (68%). A total of 95 biologic agent recommendations were extracted from the 18 recommended CPGs. Three biologic agents (Etanercept, Adalimumab, Ustekinumab) were recommended for pediatric patients. Three biologic agents (Adalimumab, Ustekinumab, Secukinumab) were recommended as first-line biologic agents for adults with psoriasis. Conclusion The overall methodological quality of CPGs for psoriasis is medium to high. More attention should be paid to applicability in guideline development. The recommendations and the basis for them among various sets guidelines were almost consistent.http://dx.doi.org/10.1080/09546634.2021.1914306psoriasisbiologic agentsclinical practice guidelinesagree ii |
| spellingShingle | Xiuli Xie Yangyang Wang Sha Yao Yun Xia Hao Luo Lui Li Chuanjian Lu Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis Journal of Dermatological Treatment psoriasis biologic agents clinical practice guidelines agree ii |
| title | Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis |
| title_full | Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis |
| title_fullStr | Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis |
| title_full_unstemmed | Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis |
| title_short | Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis |
| title_sort | biologics recommendations for patients with psoriasis a critical appraisal of clinical practice guidelines for psoriasis |
| topic | psoriasis biologic agents clinical practice guidelines agree ii |
| url | http://dx.doi.org/10.1080/09546634.2021.1914306 |
| work_keys_str_mv | AT xiulixie biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT yangyangwang biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT shayao biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT yunxia biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT haoluo biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT luili biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis AT chuanjianlu biologicsrecommendationsforpatientswithpsoriasisacriticalappraisalofclinicalpracticeguidelinesforpsoriasis |